159 related articles for article (PubMed ID: 37468541)
1. Dynamics of polyclonal immuno-reconstitution after allogeneic transplant with post-transplant cyclophosphamide and letermovir.
Orofino G; Xue E; Doglio M; Noviello M; Tassi E; Cristante M; Acerbis A; Clerici D; Farina F; Campodonico E; Bruno A; Piemontese S; Mastaglio S; Diral E; Milani R; Ruggeri A; Corti C; Vago L; Bonini C; Peccatori J; Ciceri F; Lupo Stanghellini MT; Greco R
Bone Marrow Transplant; 2023 Oct; 58(10):1104-1111. PubMed ID: 37468541
[TBL] [Abstract][Full Text] [Related]
2. Prophylactic letermovir decreases cytomegalovirus reactivation after stem cell transplantation: a single-center real-world evidence study.
Serio B; Giudice V; Guariglia R; Fontana R; Pezzullo L; Martorelli MC; Ferrara I; Mettivier L; D'Addona M; Vaccaro E; Langella M; Selleri C
Infez Med; 2021 Mar; 29(1):102-113. PubMed ID: 33664179
[TBL] [Abstract][Full Text] [Related]
3. Human Cytomegalovirus-Specific T-Cell Reconstitution and Late-Onset Cytomegalovirus Infection in Hematopoietic Stem Cell Transplantation Recipients following Letermovir Prophylaxis.
Gabanti E; Borsani O; Colombo AA; Zavaglio F; Binaschi L; Caldera D; Sciarra R; Cassinelli G; Alessandrino EP; Bernasconi P; Ferretti VV; Lilleri D; Baldanti F
Transplant Cell Ther; 2022 Apr; 28(4):211.e1-211.e9. PubMed ID: 35042012
[TBL] [Abstract][Full Text] [Related]
4. Mortality in recipients of allogeneic haematopoietic cell transplantation in the era of cytomegalovirus primary prophylaxis: a single-centre retrospective experience.
Febres-Aldana A; Khawaja F; Morado-Aramburo O; Shigle TL; Rondon G; Sassine J; Spallone A; Srinivasan K; Ramdial J; Alousi A; Champlin R; Chen G; Daher M; Rezvani K; Ariza-Heredia EJ; Shpall EJ; Chemaly RF
Clin Microbiol Infect; 2024 Jun; 30(6):803-809. PubMed ID: 38460821
[TBL] [Abstract][Full Text] [Related]
5. Letermovir Administration to Prevent Cytomegalovirus Reactivation Is the Potential Risk of Chronic Graft-
Terao T; Matsuoka KI; Narita K; Tsushima T; Yuyama S; Kuzume A; Tabata R; Miura D; Takeuchi M; Matsue K
Front Oncol; 2021; 11():666774. PubMed ID: 33996594
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of letermovir in HLA-haploidentical hematopoietic transplantation with posttransplant cyclophosphamide.
Nakagawa D; Shimomura Y; Mitsuyuki S; Kubo T; Nishikubo M; Okada N; Kamijo K; Yamamoto R; Nagai Y; Hiramoto N; Yoshioka S; Yonetani N; Ishikawa T
Int J Hematol; 2023 Sep; 118(3):347-354. PubMed ID: 37468771
[TBL] [Abstract][Full Text] [Related]
7. Increased Infections and Delayed CD4
Khimani F; Ranspach P; Elmariah H; Kim J; Whiting J; Nishihori T; Locke FL; Perez Perez A; Dean E; Mishra A; Perez L; Lazaryan A; Jain MD; Nieder M; Liu H; Faramand R; Hansen D; Alsina M; Ochoa L; Davila M; Anasetti C; Pidala J; Bejanyan N
Transplant Cell Ther; 2021 Nov; 27(11):940-948. PubMed ID: 34329754
[TBL] [Abstract][Full Text] [Related]
8. Posttransplant Cyclophosphamide and Antithymocyte Globulin versus Posttransplant Cyclophosphamide as Graft-versus-Host Disease Prophylaxis for Peripheral Blood Stem Cell Haploidentical Transplants: Comparison of T Cell and NK Effector Reconstitution.
Makanga DR; Guillaume T; Willem C; Legrand N; Gagne K; Cesbron A; Gendzekhadze K; Peterlin P; Garnier A; Le Bourgeois A; Béné MC; Chevallier P; Retière C
J Immunol; 2020 Sep; 205(5):1441-1448. PubMed ID: 32747504
[TBL] [Abstract][Full Text] [Related]
9. Comparison of immune reconstitution between anti-T-lymphocyte globulin and posttransplant cyclophosphamide as acute graft-versus-host disease prophylaxis in allogeneic myeloablative peripheral blood stem cell transplantation.
Massoud R; Gagelmann N; Fritzsche-Friedland U; Zeck G; Heidenreich S; Wolschke C; Ayuk F; Christopeit M; Kröger N
Haematologica; 2022 Apr; 107(4):857-867. PubMed ID: 33832208
[TBL] [Abstract][Full Text] [Related]
10. Real world experience: Examining outcomes using letermovir for CMV prophylaxis in high-risk allogeneic hematopoietic stem cell patients in the setting of using T-cell depletion as GVHD prophylaxis.
Dwabe S; Hsiao M; Ali A; Rodman J; Savitala-Damerla L; Nazaretyan S; Kimberly Schiff NP; Tam E; Ladha A; Woan K; Chaudhary P; Yaghmour G
Transpl Immunol; 2023 Feb; 76():101769. PubMed ID: 36464218
[TBL] [Abstract][Full Text] [Related]
11. Letermovir Discontinuation at Day 100 After Allogeneic Stem Cell Transplant Is Associated With Increased CMV-Related Mortality.
Liu LW; Yn A; Gao F; Olson M; Crain M; Abboud R; Westervelt P; Abboud C; Vij R; Stockerl-Goldstein K; Pusic I; Cashen AF; Schroeder MA
Transplant Cell Ther; 2022 Aug; 28(8):510.e1-510.e9. PubMed ID: 35598841
[TBL] [Abstract][Full Text] [Related]
12. Letermovir for Cytomegalovirus prophylaxis in pediatric hematopoietic stem cell transplantation.
Chen TT; David AP; Barthelmess EK; MacBrayne CE
Pediatr Blood Cancer; 2023 Nov; 70(11):e30608. PubMed ID: 37548491
[TBL] [Abstract][Full Text] [Related]
13. Impact of Primary Letermovir Prophylaxis vs Preemptive Antiviral Therapy for Cytomegalovirus on Economic and Clinical Outcomes after Hematopoietic Cell Transplantation.
Tan CA; Palen L; Su Y; Li Y; Gennarelli RL; Perales MA; Cohen N; Papanicolaou GA; Shah GL; Seo SK
Transplant Cell Ther; 2024 Jun; ():. PubMed ID: 38838781
[TBL] [Abstract][Full Text] [Related]
14. Improved NK Cell Recovery Following Use of PTCy or Treg Expanded Donors in Experimental MHC-Matched Allogeneic HSCT.
Wolf D; Barreras H; Copsel SN; Komanduri KV; Levy RB
Transplant Cell Ther; 2022 Jun; 28(6):303.e1-303.e7. PubMed ID: 35302008
[TBL] [Abstract][Full Text] [Related]
15. Risk of Cytomegalovirus Infection with Post-Transplantation Cyclophosphamide in Haploidentical and HLA-Matched Unrelated Donor Transplantation.
Jamy O; Hebert C; Dunn-Valadez S; Magnusson T; Watts N; McGwin G; Saad A
Transplant Cell Ther; 2022 Apr; 28(4):213.e1-213.e6. PubMed ID: 35074557
[TBL] [Abstract][Full Text] [Related]
16. Post-transplant cyclophosphamide alters immune signatures and leads to impaired T cell reconstitution in allogeneic hematopoietic stem cell transplant.
Zhao C; Bartock M; Jia B; Shah N; Claxton DF; Wirk B; Rakszawski KL; Nickolich MS; Naik SG; Rybka WB; Ehmann WCC; Hohl RJ; Valentin J; Bernas-Peterson M; Gerber EM; Zimmerman M; Mierski JA; Mineishi S; Zheng H
J Hematol Oncol; 2022 May; 15(1):64. PubMed ID: 35590334
[TBL] [Abstract][Full Text] [Related]
17. Letermovir for Prevention of Cytomegalovirus Reactivation in Haploidentical and Mismatched Adult Donor Allogeneic Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide for Graft-versus-Host Disease Prophylaxis.
Lin A; Flynn J; DeRespiris L; Figgins B; Griffin M; Lau C; Proli A; Devlin SM; Cho C; Tamari R; Jakubowski AA; Papadopoulos EB; Giralt SA; Perales MA; Seo SK; Shaffer B
Transplant Cell Ther; 2021 Jan; 27(1):85.e1-85.e6. PubMed ID: 33053449
[TBL] [Abstract][Full Text] [Related]
18. Features of cytomegalovirus DNAemia and virus-specific T-cell responses in allogeneic hematopoietic stem-cell transplant recipients during prophylaxis with letermovir.
Giménez E; Guerreiro M; Torres I; Aguilar C; Albert E; Hernández-Boluda JC; Hernani R; Pérez A; Amat P; Piñana JL; Montoro J; Solano C; Navarro D
Transpl Infect Dis; 2023 Apr; 25(2):e14021. PubMed ID: 36748748
[TBL] [Abstract][Full Text] [Related]
19. Extended letermovir administration, beyond day 100, is effective for CMV prophylaxis in patients with graft versus host disease.
Bansal R; Gordillo CA; Abramova R; Assal A; Mapara MY; Pereira MR; Reshef R
Transpl Infect Dis; 2021 Apr; 23(2):e13487. PubMed ID: 33034124
[TBL] [Abstract][Full Text] [Related]
20. CD4+ T cells are the major predictor of HCMV control in allogeneic stem cell transplant recipients on letermovir prophylaxis.
Lauruschkat CD; Muchsin I; Rein A; Erhard F; Grathwohl D; Dölken L; Köchel C; Falk CS; Einsele H; Wurster S; Grigoleit GU; Kraus S
Front Immunol; 2023; 14():1148841. PubMed ID: 37234158
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
